The promise and peril of chemical probesC.H. Arrowsmith, Michael A. Walters, Carolyn Buser‐Doepner et al.|Nature Chemical Biology|2015Cited by 848
Chromatin proteins and modifications as drug targetsKristian Helin, Dashyant Dhanak|Nature|2013Cited by 423
A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blockerEwa Rakowski, Adel Giaid, Ghada S. Hassan et al.|Journal of Molecular and Cellular Cardiology|2005Cited by 59
Preclinical target validation using patient-derived cellsA.M. Edwards, Kevin Petrecca, C.H. Arrowsmith et al.|Nature Reviews Drug Discovery|2015Cited by 54
A Blueprint for an International Cancer Epigenome Consortium. A Report from the AACR Cancer Epigenome Task ForceStephan Beck, Peter A. Jones, B Bernstein et al.|Cancer Research|2012Cited by 25